185 related articles for article (PubMed ID: 21936551)
21. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
Liu Y; Salvador LA; Byeon S; Ying Y; Kwan JC; Law BK; Hong J; Luesch H
J Pharmacol Exp Ther; 2010 Nov; 335(2):351-61. PubMed ID: 20739454
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole.
Bowers AA; Greshock TJ; West N; Estiu G; Schreiber SL; Wiest O; Williams RM; Bradner JE
J Am Chem Soc; 2009 Mar; 131(8):2900-5. PubMed ID: 19193120
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold.
Bowers AA; West N; Newkirk TL; Troutman-Youngman AE; Schreiber SL; Wiest O; Bradner JE; Williams RM
Org Lett; 2009 Mar; 11(6):1301-4. PubMed ID: 19239241
[TBL] [Abstract][Full Text] [Related]
24. Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8.
Decroos C; Clausen DJ; Haines BE; Wiest O; Williams RM; Christianson DW
Biochemistry; 2015 Mar; 54(12):2126-35. PubMed ID: 25793284
[TBL] [Abstract][Full Text] [Related]
25. Unexpected Enhancement of HDACs Inhibition by MeS Substitution at C-2 Position of Fluoro Largazole.
Zhang B; Ruan ZW; Luo D; Zhu Y; Ding T; Sui Q; Lei X
Mar Drugs; 2020 Jun; 18(7):. PubMed ID: 32629787
[TBL] [Abstract][Full Text] [Related]
26. A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling.
Liu Y; Wang Z; Wang J; Lam W; Kwong S; Li F; Friedman SL; Zhou S; Ren Q; Xu Z; Wang X; Ji L; Tang S; Zhang H; Lui EL; Ye T
Liver Int; 2013 Apr; 33(4):504-15. PubMed ID: 23279742
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and activity of largazole analogues with linker and macrocycle modification.
Ying Y; Liu Y; Byeon SR; Kim H; Luesch H; Hong J
Org Lett; 2008 Sep; 10(18):4021-4. PubMed ID: 18707106
[TBL] [Abstract][Full Text] [Related]
28. Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells.
Zhang K; Yao Y; Tu Z; Liao C; Wang Z; Qiu Y; Chen D; Hamilton DJ; Li Z; Jiang S
Future Med Chem; 2020 Feb; 12(4):311-323. PubMed ID: 31782319
[No Abstract] [Full Text] [Related]
29. Enantioselective total synthesis of (+)-largazole, a potent inhibitor of histone deacetylase.
Ghosh AK; Kulkarni S
Org Lett; 2008 Sep; 10(17):3907-9. PubMed ID: 18662003
[TBL] [Abstract][Full Text] [Related]
30. Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5''-epi-spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity.
Narita K; Kikuchi T; Watanabe K; Takizawa T; Oguchi T; Kudo K; Matsuhara K; Abe H; Yamori T; Yoshida M; Katoh T
Chemistry; 2009 Oct; 15(42):11174-86. PubMed ID: 19760730
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
Gong CJ; Gao AH; Zhang YM; Su MB; Chen F; Sheng L; Zhou YB; Li JY; Li J; Nan FJ
Eur J Med Chem; 2016 Apr; 112():81-90. PubMed ID: 26890114
[TBL] [Abstract][Full Text] [Related]
32. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
Zhou M; Ning C; Liu R; He Y; Yu N
Bioorg Med Chem Lett; 2013 Jun; 23(11):3200-3. PubMed ID: 23639537
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton.
Sun S; Zhao W; Li Y; Chi Z; Fang X; Wang Q; Han Z; Luan Y
Bioorg Chem; 2021 Mar; 108():104652. PubMed ID: 33497873
[TBL] [Abstract][Full Text] [Related]
35. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of Santacruzamate-A based analogues.
Randino R; Gazzerro P; Mazitschek R; Rodriquez M
Bioorg Med Chem; 2017 Dec; 25(24):6486-6491. PubMed ID: 29100734
[TBL] [Abstract][Full Text] [Related]
37. A fluorine scan on the Zn
Zhang B; Liu J; Gao D; Yu X; Wang J; Lei X
Eur J Med Chem; 2019 Nov; 182():111672. PubMed ID: 31505452
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
[TBL] [Abstract][Full Text] [Related]
39. Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere.
Pilon JL; Clausen DJ; Hansen RJ; Lunghofer PJ; Charles B; Rose BJ; Thamm DH; Gustafson DL; Bradner JE; Williams RM
Cancer Chemother Pharmacol; 2015 Apr; 75(4):671-82. PubMed ID: 25616967
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of the thiazole-thiazoline fragment of largazole analogues.
Diness F; Nielsen DS; Fairlie DP
J Org Chem; 2011 Dec; 76(23):9845-51. PubMed ID: 22032297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]